Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL39811 | 0.90 | POLA1 (0.38) | POLA1 | |
| SCHEMBL3796115 | 0.88 | POLA1 (0.43) | POLA1 | |
| SCHEMBL5856686 | 0.87 | POLA1 (0.32) | POLA1 | |
| SCHEMBL2957305 | 0.87 | POLA1 (0.46) | POLA1 | |
| SCHEMBL39621 | 0.85 | — | — | |
| SCHEMBL11490524 | 0.81 | — | — | |
| SCHEMBL16240897 | 0.81 | ALDH1A1 (0.37) | — | |
| SCHEMBL28737678 | 0.80 | NPC1 (0.38) | — | |
| SCHEMBL28589723 | 0.79 | — | — | |
| Hydrochloric Acid SCHEMBL953800 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112689501-B | Make-up preparation | 陶氏环球技术有限责任公司 | 2023-05-16 | — | — | CN | disclosed |
| CN-115227880-A | Drug-coated balloon catheter for body lumens | 优敦力公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-2584896-A2 | HERBICIDAL COMPOSITIONS | BASF SE (DE) | 2013-05-01 | — | — | EP | disclosed |
| US-20130102463-A1 | Herbicidal Compositions | BASF SE (DE) | 2013-04-25 | — | — | US | disclosed |
| WO-2011161105-A2 | HERBICIDAL COMPOSITIONS | BASF SE (DE) | 2011-12-29 | — | — | WO | disclosed |
| US-20080287389-A1 | Nucleoside analogs in combination therapy of herpes simplex infections | NOVARTIS PHARMACEUTICALS CORPORATION | 2008-11-20 | — | — | US | disclosed |
| EP-1389131-A2 | COMBINATIONS OF A 5HT1 RECEPTOR AGONIST WITH AN ANALGESIC, AND AN ANTI-EMETIC AND/OR A GASTROPROKINETIC AGENT | GLAXO GROUP LIMITED (GB) | 2004-02-18 | — | — | EP | disclosed |
| WO-2002067987-A2 | COMBINATIONS OF A 5HT1 RECEPTOR AGONIST WITH AN ANALGESIC, AND AN ANTI-EMETIC AND/OR A GASTROPROKINETIC AGENT | GLAXO GROUP LIMITED (GB) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102463-A1 | Herbicidal Compositions | PPOX, PAOX, DDT | POLA1 1995/4885 |
| US-20080287389-A1 | Nucleoside analogs in combination therapy of herpes simplex infections | TYMP, PNP, PAICS | POLA1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.